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Abstract
Background Inhibition of the nuclear factor kappa beta
(NF-jb) pathway has been proposed as a therapeutic target
due to its key role in the expression of pro-inflammatory
genes, including pro-inflammatory cytokines, chemokines,
and adhesion molecules. Caffeic acid phenethyl ester
(CAPE) is a naturally occurring anti-inflammatory agent,
found in propolis, and has been reported as a specific
inhibitor of NF-jb. However, the impact of CAPE on
levels of myeloperoxidases (MPO) and pro-inflammatory
cytokines during inflammation is not clear. The aims of this
study were to investigate the protective efficacy of CAPE
in the mouse model of colitis and determine its effect on
MPO activity, pro-inflammatory cytokines levels, and
intestinal permeability.
Method Dextran sulphate sodium was administered in
drinking water to induce colitis in C57/BL6 mice before
treatment with intraperitoneal administration of CAPE
(30 mg kg-1 day-1). Disease activity index (DAI) score,
colon length and tissue histology levels of MPO, pro-in-
flammatory cytokines, and intestinal permeability were
observed.
Results CAPE-treated mice had lower DAI and tissue
inflammation scores, with improved epithelial barrier pro-
tection and significant reduction in the level of MPO and
pro-inflammatory cytokines.
Conclusion Our results show that CAPE is effective in
suppressing inflammation-triggered MPO activity and pro-
inflammatory cytokines production while enhancing
epithelial barrier function in experimental colitis. Thus, we
conclude that CAPE could be a potential therapeutic agent
for further clinical investigations for treatment of inflam-
matory bowel diseases in humans.
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Introduction
Inflammatory bowel disease (IBD) is an idiopathic disor-
der, generally categorised as either Crohn’s disease (CD) or
ulcerative colitis (UC) (Neurath 2014; Ford et al. 2011).
There is no therapeutic cure for IBD and the current disease
management strategies possess several drawbacks. For
example, immunomodulatory agents, such as azathioprine
and 6-mercaptopurine, cause bone marrow depletion and
damage to both white blood cell and hepatic cell popula-
tions. Furthermore, results from recent clinical trials
confirm that azathioprine is ineffective in UC (Ardizzone
et al. 2006; Kamath et al. 2016; O’Connor et al. 2010) and
sulfasalazine causes ruptures in liver tissue and decreases
platelets count in blood (de Abajo et al. 2004; Rubin 1994).
Furthermore, pulmonary disorders are reported in IBD
patients treated with chimeric monoclonal antibodies, such
as infliximab (Patel et al. 2016).
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The clinical symptoms of IBD range from episodes of
relapse and remission with mild inflammation and dis-
comfort to a chronic ulcerative disease requiring surgical
removal of the inflamed gut. The current therapeutic
strategies for IBD are generally limited, but recent clinical
advancement has occurred in immunotherapy using mon-
oclonal antibodies. This approach is directed against
inflammatory mediators, such as TNF-a (Targan 2006;
Subramanian et al. 2017; Gecse and Lakatos 2017; Chan
and Ng 2017). However, these biological agents are
expensive and result in severe side effects and life threat-
ening complications (Cote-Daigneault et al. 2015; Blonski
and Lichtenstein 2006; Clarke and Regueiro 2012; Cohen
and Thomas 2006). Hence, there is a need in the field of
IBD therapy to develop new therapeutics, which are
effective, safe, and economical. One way to achieve this is
investigation into the anti-inflammatory effect of natural
compounds and understanding their mechanism of action.
Lack of specificity and the encumbrance of severe side
effects necessitate further investigation into effective and
safer options for treating IBD (Pichai and Ferguson 2012),
which is the aim of this current study.
Colonic specimens from UC patients display overex-
pression of transcription factor nuclear factor kappa beta
(NF-jb) (Atreya et al. 2008). NF-jb is up regulated by
TNF-a, interleukin (IL), interferon, chemokines, and DNA
damaging agents during the inflammatory phase. Similar
effects are observed following exposure to lipopolysac-
charide derived from bacterial cell wall components
(Lawrence 2009b; Xavier and Podolsky 2007). In UC,
levels of inflammatory mediators, such as TNF-a, inter-
leukins, and interferons, increase due to the over
stimulation of NF-jb during inflammation (Schreiber et al.
1998). It is feasible, therefore, that inhibition of NF-jb
may be of therapeutic benefit in UC, which forms the
hypothesis of our current work.
Novel pharmacological inhibitors of NF-jb are cur-
rently available, but these compounds inflect toxicity and
severe side effects in humans. Hence, we have selected
caffeic acid phenethyl ester (CAPE), a phenolic constituent
derived from honeybee propolis and shown in Fig. 1, for
further study. It possesses no known adverse side effects
(Tolba et al. 2014; Liao et al. 2003). CAPE possesses
potent anti-inflammatory properties, which are attributed to
its selective inhibition of NF-jb. Recently, CAPE has been
reported to inhibit other relevant pathways, such as MAPK
and PI3K (Natarajan et al. 1996; Ozturk et al. 2012; Lin
et al. 2013; Pramanik et al. 2013; Cho et al. 2014). CAPE
represses translocation of NF-jb, either by inhibition of
Ijb degradation or by blocking of NF-jb and DNA binding
(Wang et al. 2010; Bezerra et al. 2012). It has been
reported that inflammatory markers, such as INF-!, IL-6,
IL-b, TNF-a, and IL-10, cause degradation of Ijb, which
results in induced overexpression of NF-jb (Lang et al.
2004). CAPE inhibits this overexpression of NF-jb via
prevention of degradation of Ijb (Wang et al. 2010; Lee
et al. 2008).
The most recent evaluation of the anti-inflammatory
activity of CAPE has been limited to either cell culture
models or rat models of 2,4,6-trinitrobenzenesulfonic acid-
peptidoglycan polysaccharide-induced UC (Armutcu et al.
2015; Ek et al. 2008; Fitzpatrick et al. 2001; Kim et al.
2013). However, the pathophysiological mechanism, such
as macroscopic, microscopic changes in the colon and
effect on pro-inflammatory cytokine levels, and mucosal
barrier function, by which CAPE exerts its anti-inflam-
matory activity, have not been fully explored (Fitzpatrick
et al. 2001; Michaluart et al. 1999; Ek et al. 2008; Cooper
et al. 1993). Hence, the activity of CAPE has not been
studied in relevant in vivo models, which are physiologi-
cally more representative of the human disease (Chassaing
et al. 2014). Thus, the main aspect of this study, which
differentiates it from the previous work, is assessment of
the activity of CAPE on the colon at macroscopic and
microscopic levels, its effect on MPO and pro-inflamma-
tory cytokine levels and altered mucosal permeability in a
mouse model of colitis, which is physiologically relevant to
human disease (Tambuwala et al. 2015). The findings of
this study will provide an insight into the anti-inflammatory
efficacy of CAPE during colitis in terms of changes in the
levels of the disease activity index (DAI) score, colon
MPO, pro-inflammatory cytokines, and epithelial barrier
function.
Materials and methods
Materials
Caffeic acid phenethyl ester (97%) was purchased from
Sigma-Aldrich Ltd. (Dorset, UK) and dextran sodium
sulphate (DSS) was procured from MP Biomedicals
(Bedford, UK) (molecular weight 36,000–50,000). CAPE
was administered by IP injection at a dose of 30 mg kg-1
on a daily basis for 7 days. The injection was prepared by
dissolving CAPE (1.0 mg) in 1.0 ml of sterile aqueous
solution containing 25% PEG 200.Fig. 1 Chemical structure of caffeic acid phenethyl ester (CAPE)
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Dextran sodium sulphate model of induced colitis
For DSS colitis-induced experiments, 12-week-old C57BL/
6 female mice were used (Charles River, UK). The Ulster
University Animal Research Ethics Committee and UK
Home Office approved all procedures described, under
Project license (PL2768).
Colitis was induced by administering 2.5% w/v DSS in
drinking water over a period of 7 days. The DAI score was
used to record morphological changes, such as weight loss,
stool consistency, and presence of blood in faeces. On
termination of the experiment, mice were sacrificed by
cervical dislocation (Egger et al. 2000; Okayasu et al.
1990). The isolated colon was excised, washed in PBS, and
laid flat on moist tissue to measure its length. Sections,
approximately 1.0 cm, of excised colonic tissue were fixed
in 10% paraformaldehyde (pH 7.4; phosphate-buffered
saline) and embedded in paraffin. Sections (4 lm) were cut
and stained with hematoxylin and eosin. Histologic
assessment and scoring of colon tissue sections were car-
ried out in a blinded fashion based on previously defined
parameters (Sutherland et al. 1987). All tissue slides were
imaged using light a microscopy at 59 and 109
magnifications.
Colon cytokine and myeloperoxidases measurements
Post-mortem colon tissue was homogenised using a method
adapted from processing lung tissue (Mangan et al. 2006).
Levels of pro-inflammatory cytokines, such as INF-c, IL-6,
IL1-b, TNF-a, and IL-10, were detected using V-Plex
Assay Plates (Meso Scale Diagnostics; Rockville, MD,
USA) and assayed as per the manufacturer’s protocol.
MPO activity was detected using o-phenylenediamine
dihydrochloride as substrate and the data were interpolated
from an MPO standard curve (Sigma). Levels of cytokines
and MPO were expressed as pg per mg or U per mg,
respectively, relative to colon protein (Cummins et al.
2008).
Assessment of NF-jb activation in colon tissue
Colon tissue was homogenised and lysate then analysed for
NF-jb/p65 levels using a Nuclear Extraction kit (Ac-
tiveMotif, Carlsbad, USA) in accordance with the
manufacturer’s protocol (Lin et al. 2014).
In vivo intestinal permeability measurements
Mice were exposed to 7 days of DSS treatment, which was
followed by standard oral gavage of fluorescein isothio-
cyanate (FITC)-labelled dextran (4 kDa) at a dose of
0.6 mg g-1 of body weight. Mice were euthanised 4 h later
and blood removed by cardiac puncture. Plasma was sep-
arated and FITC levels in plasma determined by
fluorometry (Tambuwala et al. 2010).
Statistical analysis
Results were expressed as mean ± standard error of the
mean (SEM) for a series of experiments. Data were
assumed to be normally distributed and statistical analyses
were carried out using Prizm GraphPad V6 software
(GraphPad, San Diego, CA, USA). A paired t test was used
for comparisons of paired treatments between two groups,
unpaired t tests for comparisons of unpaired treatments
between two groups, and one-way ANOVA using Bon-
ferroni multiple comparisons tests for treatments of three
groups or more. P values B0.05 were considered to be
significant.
Ethical considerations
The Ulster University Animal Research Ethics Committee
and UK Home Office approved all procedures described,
under Project license (PL2768). Severity levels were gra-
ded as mild by the UK Home office.
Results
CAPE ameliorates disease in DSS-induced colitis
It has been reported by us and several researchers that
colitis is a collection of symptoms, such as weight loss,
diarrhoea, and blood in faeces, collectively described by
the DAI and shortening of colon length (Ogawa et al. 2004;
Taghipour et al. 2016; Chassaing et al. 2014; Chen et al.
2007). To study the protective effect of CAPE on mice
with DSS-induced colitis, we recorded the weight of each
mouse in all groups daily for 7 days. Figure 2a shows
significantly (P\ 0.001) lowered weight loss in
DSS ? CAPE-treated mice when compared to the DSS-
only group. Similarly, Fig. 2b shows that mice in the DSS-
alone group had the highest DAI score, which confirmed
the development of colitis. Mice treated with CAPE
showed a significantly (P\ 0.01) lower DAI score, when
comparison is made to the DSS-only group. This finding
suggests that CAPE was protecting mice against weight
loss and the occurrence of diarrhoea and appearance of
blood in faeces during DSS-induced colitis.
Shortening of the colon is one of the clinical signs of
colitis (Tambuwala et al. 2015). Figure 3a shows repre-
sentative image from the colon of a healthy mouse with
well-formed stool pellets. In contrast, there were no formed
stools and blood observed in the colon of mice treated with
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DSS alone. However, semi-formed stools and no blood
were visible in the colon of mouse treated with CAPE. A
graphical presentation of the average colon length of each
group is shown in Fig. 3b. It was observed that there was
significant (P\ 0.001) reduction in colon length in mice
treated with DSS alone when compared to the healthy
control and DSS ? CAPE-treated mice. Thus, CAPE
treatment attenuated the impact of DSS on colon length
reduction and also assisted stool formation.
Histological examination of colon tissue confirmed that
DSS treatment caused extensive colonic damage with lose
of epithelium and collapse of crypt structure. This was
accompanied by oedema and infiltration of inflammatory
neutrophils (Fig. 4a). In contrast, there was a marked
reduction in severity of DSS-induced colon injury in
CAPE-treated mice. The crypt architecture showed that no
ulceration or evidence of oedema, lesser degree of infil-
tration of inflammatory cells, and neutrophils were
Fig. 2 Lowered percentage weight loss and DAI score in mice
treated with CAPE during DSS-induced colitis. a Percentage weight
loss was assessed in mice treated with DSS-alone (red line), DSS and
CAPE (green line), and no DSS healthy mice (black line). b Disease
activity index was assessed in mice treated with DSS-alone (red line),
DSS and CAPE (green line), and no DSS healthy mice (black line)
over 7 days. Each control and experimental group contained a
minimum of 5–6 individual mice (P\ 0.001–0.01)
Fig. 3 CAPE treatment is effective in protecting gross anatomy and
colon length. a Gross appearance of the colonic anatomy shows the
effect of CAPE on DSS-induced colon shortening and formation of
fecal pellets. b Colon length was measured at post-mortem autopsy
(P\ 0.001). N = 5–6 mice per group
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observed in the colon histology of mice receiving CAPE
treatment (Fig. 4a). The blinded histological scoring of
colon tissue histology revealed a significant reduction of
damage in the colon of CAPE-treated mice relative to
healthy control mice (P\ 0.001; Fig. 4b). To confirm that
CAPE downregulated the NF-jb pathway in DSS-induced
colitis, we assessed the levels of p65 in colon tissue. There
was a marked increase in the level of p65 in DSS-alone
group and the mice treated with CAPE showed a significant
reduction in the level of p65 (Supplementary Figure 1).
We next investigated the impact of CAPE treatment of
the expression of markers of colonic inflammation that are
increased in mice exposed to DSS. DSS-alone control mice
showed a significant increase in MPO activity, a marker for
inflammation, and leukocyte infiltration (P\ 0.01;
Fig. 5a). However, exposure of CAPE-treated mice to DSS
did not result in increased colon MPO levels (Fig. 5a). We
also noted that colonic levels of pro-inflammatory cytoki-
nes, such as INF-c, IL6, IL1-b, TNF-a, and IL10 (Fig. 5b–
e), were significantly (P\ 0.001) increased in mice with
DSS-induced colitis, as compared to healthy mice. Co-
administration of CAPE resulted in small increases in INF-
c, IL1-b, TNF-a, and IL10, which were not significantly
different from that of the healthy control. Thus, the DSS-
induced colitis resulted in an increase in MPO, INF-c, IL6,
IL1-b, TNF-a, and IL10. All were diminished significantly
in CAPE-treated mice (P\ 0.01–0.001). Although IL-10 is
known to play a protective role in colitis, we observed a
small decrease in IL-10 levels in mice treated with CAPE,
which was expected as CAPE is known to lower the levels
of IL-10 (Sy et al. 2011). Furthermore, treatment of mice
with CAPE alone had no effects on MPO, INF-c, IL6, IL1-
b, and TNF-a (data not shown).
Enhanced epithelial barrier function in mice treated
with CAPE
To investigate the effect of CAPE treatment on the
intestinal epithelial integrity, in vivo barrier function was
measured in healthy mice, mice exposed to DSS and mice
co-treated with CAPE and DSS. An oral dose of FITC-
dextran was administered to mice on the last day of DSS
exposure. Four hours later, FITC levels in plasma were
determined as a measure of intestinal permeability. The
DSS-only group of mice exhibited a significant increase in
intestinal permeability, which was reflected by an increased
appearance of FITC in plasma. This effect was markedly
diminished in mice treated with CAPE (Fig. 6a;
P\ 0.001), indicating that co-treatment with CAPE during
DSS-induced colitis reduces the leakiness of the colon and
maintains the epithelial barrier function.
Discussion
The previous studies have indicated that CAPE is an
effective inhibitor of NF-jb and related cytokines in vitro,
and also has the ability induce apoptosis in inflammatory
Fig. 4 Improved colon histological outcome in mice treated with CAPE. a Representative histological images of colonic tissue showing the
effect of CAPE treatment (H&E staining). b Histological scores of sections scored blinded. N = 5–6 mice per group (P\ 0.001)
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cells (Fitzpatrick et al. 2001). In our current study, we have
shown for the first time that CAPE significantly amelio-
rates the severity of the disease in a mouse model of UC.
One of the initial events that occur during the onset of
IBD is disruption of the intestinal epithelial barrier func-
tion. This dysfunction leads to unwanted movement of
luminal antigenic material into the lamina propria. This is
Fig. 5 Effect of CAPE on expression of pro-inflammatory mediators. The colon tissue homogenates analysed for aMPO, b INF-!, c IL-6, d IL-
b, e TNF-a, and f IL-10. N = 5–6 mice per group (P\ 0.001)
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followed by activation of mucosal immune cells and trig-
gering of an inflammatory response. It has been suggested
that one of the critical events in the development of
inflammation in the intestine could be the regulation of
intestinal epithelial cell apoptosis (Cummins et al. 2008;
Tambuwala et al. 2010). In cases of chronic inflammation
during IBD, constant intestinal epithelial cell apoptosis
could lead the loss of the epithelial barrier, which will
result in spread of inflammation, resulting in increased
severity of the disease. This creates an imbalance in the
innate and adaptive immunity of the gut (Nenci et al. 2007;
Zaph et al. 2007).
In the present work, we have shown for the first time
that CAPE, a potent inhibitor NF-jb, is profoundly pro-
tective in an in vivo mouse model of acute colonic
inflammation. Although we hypothesise that the protective
effects of CAPE are mediated through the inhibition of the
over activation of the NF-jb pathway, we cannot exclude
the possibility of NF-jb independent mechanisms of
action, such as inhibition of hydroxylases and activation of
hypoxia inducible pathways (Cummins et al. 2008).
However, several researchers have indicated that the NF-
jb pathway plays an important role during intestinal
inflammation (Wei and Feng 2010; Buhrmann et al. 2011;
Lawrence 2009a; Fitzpatrick et al. 2001) and inhibition of
this pathway targets pro-inflammatory cytokines, such as
interferons and tumour necrosis factor alpha. These are
known to play key role during the development and
progression of UC (Baird et al. 2016; Bishop et al. 2014;
Ferrari et al. 2016).
CAPE treatment significantly ameliorated the severity of
disease after acute DSS exposure in all parameters studied,
including weight loss (Fig. 2a), clinical DAI score
(Fig. 2b), reduction of colon length, and appearance of
blood in faeces (Fig. 3a, b). A marked improvement in
colon histology was observed (Fig. 4a), together with
improved blinded inflammation scores (Fig. 4b). In the
murine model of DSS-induced colitis, the increase in MPO
and pro-inflammatory cytokines occurred after the disrup-
tion to the intestinal barrier, indicating that compromised
barrier function results in progression inflammation.
CAPE-treated mice did not have increased MPO (Fig. 5a)
and only small increase in other pro-inflammatory cytoki-
nes (Fig. 5b–f), suggesting that CAPE treatment prevented
the damage to colon epithelial cells caused by DSS and
helps in maintaining the epithelial barrier function, which
is evident by reduced permeability of FITC in mice treated
with CAPE (Fig. 6). However, whether improved epithelial
barrier function or indeed lowered cytokine expression is
the cause or consequence of the protective effects of CAPE
remains to be elucidated. This critical question will be the
topic of further investigations.
In mice treated with CAPE, in the absence of DSS
exposure, there were no alterations in MPO or cytokines in
the colon and no alterations in colon histology or length.
This confirms that in the acute 6-day treatment regimen
used in this study, CAPE did not alter physiologic
inflammation in normal tissue, but instead suppressed
inflammation in the colon when occurred due to DSS-in-
duced disruption of the barrier function.
In this study, we have observed that there was an
increase in NF-jb activity in the colon of mice treated with
DSS and that CAPE downregulates this increase, thereby
exerting a protective event in a mouse model of UC. Since
CAPE is a natural compound, with no known side effects
(Tambuwala 2016), its therapeutic benefits are obvious and
desirable when measured up against over other novel
compounds with pro-tumorigenic effects; such as DMOG,
which have also shown to be protective in experimental
colitis (Cummins et al. 2008). The findings of this work
indicate that CAPE can be used an effective first-line
treatment for patients with UC, improving intestinal barrier
function and halting the progression of disease, whilst
promoting mucosal healing. The next stage of our work
will focus on two elements, namely (1) development of
nanoparticle-based colonic drug delivery of CAPE, which
could allow for local delivery of the drug to inflamed tissue
to ensure effective therapeutic outcomes using a lower dose
and (2) identification of the NF-jb subunit most affected
by CAPE.
Fig. 6 Reduced epithelial permeability in mice treated with CAPE.
Mice treated with DSS with or without CAPE (30 mg/kg) IP and
healthy mice were administered 4 kDa-FITC-labelled dextran orally,
and serum levels of FITC were assessed. Each control and experi-
mental group contains 5–6 mice (P\ 0.001)
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